VEGFA and esophageal squamous cell carcinoma: These antibodies effectively block oncogenic phenotypes in vitro, suppress tumorigenesis in xenograft models, such as in ESCC [40], and inhibit VEGF-induced angiogenesis both ex vivo and in vivo [29].